home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9407a.zip
/
M9470046.TXT
< prev
next >
Wrap
Text File
|
1994-07-02
|
2KB
|
37 lines
Document 0046
DOCN M9470046
TI Jacalin, a lectin with anti-HIV-1 properties, and HIV-1 gp120 envelope
protein interact with distinct regions of the CD4 molecule.
DT 9409
AU Corbeau P; Haran M; Binz H; Devaux C; CRBM-UPR 9008 du CNRS, Institut de
Biologie-Faculte de; Medecine, Montpellier, France.
SO Mol Immunol. 1994 Jun;31(8):569-75. Unique Identifier : AIDSLINE
MED/94254890
AB Jacalin is a multimeric plant lectin able to interact with the
lymphocyte cell-surface molecule CD4, a known receptor for the human
immunodeficiency virus type 1 (HIV-1). Moreover, jacalin is able to
block HIV-1 infection of CD4+ lymphoblastoid cells. Here we studied
whether jacalin prevents HIV-1 gp120-CD4 interactions. We found (i) that
jacalin did not inhibit HIV-1 Lai-induced syncytium formation that
requires gp120-CD4 interactions; (ii) that jacalin prevented neither
rgp120 binding to cell-surface CD4 nor sCD4 binding to viral envelope
proteins expressed at the surface of HIV-1-infected lymphoblastoid
cells; (iii) that jacalin did not compete for binding to CD4 with
anti-CD4 mAb specific for the CDR2- or CDR3-like regions of the D1
domain of CD4; (iv) that jacalin did not bind a recombinant soluble
molecule containing the D1/D2 domains of CD4; and, (iv) that jacalin
binding to CD4 is inhibited by sugars known to interact with the
lectinic-site of jacalin. These data have implications for the
understanding of the mechanism by which jacalin blocks HIV-1 infection
of CD4+ cells.
DE Acetylgalactosamine/METABOLISM Antigens, CD4/CHEMISTRY/*METABOLISM
Antiviral Agents/*METABOLISM Binding Sites Binding, Competitive Cell
Line Cell Line, Transformed Comparative Study Human HIV Envelope
Protein gp120/*METABOLISM HIV-1/*DRUG EFFECTS Lectins/*METABOLISM
Nitrophenylgalactosides/METABOLISM Support, Non-U.S. Gov't JOURNAL
ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).